L
Lorantis
Products for the selective treatment of immunological and inflammatory diseases
About Lorantis
Lorantis was a biotechnology firm that focused on discovering and developing products to address immunological and inflammatory diseases. The company's scientific foundation was built upon leveraging antigen-specific tolerance to create new therapeutic interventions.
Based in Cambridge, UK, Lorantis operated within the biopharmaceutical sector, concentrating its research and development efforts on novel treatments. Its pipeline included protein therapeutics based on the Notch signaling pathway, which were in preclinical development for immune disorders. One of the company's key programs was HepVax, a vaccine for Hepatitis B, which was anticipated to move into Phase I trials in early 2006.
In a significant milestone, Lorantis was acquired by Celldex Therapeutics in October 2005. The deal was structured with an exchange of 6.8 million Celldex shares. At the time of the acquisition, Lorantis also held approximately $30 million in cash, which was part of the transaction. This acquisition marked the conclusion of Lorantis's journey as an independent entity, integrating its promising research programs and assets into Celldex's portfolio.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1998
- Headquarters
- Cambridge, United Kingdom
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Oct 2005 | $33M | $132M | Apax Partners · Wellcome Trust | — |
| SERIES A✓Equity / VC | Jun 2000 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Lorantis is 130 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Apax Partners
Wellcome Trust
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lorantis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lorantis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.